Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from Oppenheimer

Oppenheimer reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report report published on Wednesday, AnalystRatings.com reports. Oppenheimer currently has a $12.00 price objective on the biotechnology company’s stock.

VKTX has been the subject of several other reports. Maxim Group started coverage on Viking Therapeutics in a report on Saturday, May 2nd. They set a buy rating and a $14.00 price objective for the company. Stifel Nicolaus reiterated a buy rating and set a $14.00 price objective on shares of Viking Therapeutics in a report on Wednesday. BidaskClub lowered Viking Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 15th. BTIG Research started coverage on Viking Therapeutics in a report on Friday, May 1st. They set a buy rating and a $9.00 price objective for the company. Finally, BMO Capital Markets started coverage on Viking Therapeutics in a report on Thursday, June 4th. They set an outperform rating and a $14.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Viking Therapeutics presently has a consensus rating of Buy and a consensus price target of $14.78.

Shares of Viking Therapeutics stock opened at $7.02 on Wednesday. The business has a fifty day simple moving average of $7.11 and a 200-day simple moving average of $6.41. Viking Therapeutics has a 12 month low of $3.26 and a 12 month high of $8.87.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. As a group, analysts predict that Viking Therapeutics will post -0.6 earnings per share for the current fiscal year.

In other news, Director Matthew W. Foehr sold 13,000 shares of Viking Therapeutics stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $7.35, for a total value of $95,550.00. Following the transaction, the director now directly owns 26,250 shares in the company, valued at $192,937.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.70% of the company’s stock.

Several institutional investors have recently bought and sold shares of VKTX. Great West Life Assurance Co. Can bought a new position in shares of Viking Therapeutics in the fourth quarter worth about $30,000. Credit Suisse AG increased its stake in shares of Viking Therapeutics by 255.1% in the fourth quarter. Credit Suisse AG now owns 139,696 shares of the biotechnology company’s stock worth $1,120,000 after purchasing an additional 100,356 shares during the period. Stifel Financial Corp increased its stake in shares of Viking Therapeutics by 59.4% in the fourth quarter. Stifel Financial Corp now owns 34,854 shares of the biotechnology company’s stock worth $290,000 after purchasing an additional 12,991 shares during the period. Amalgamated Bank bought a new position in shares of Viking Therapeutics in the fourth quarter worth about $84,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Viking Therapeutics by 49.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 142,755 shares of the biotechnology company’s stock worth $1,145,000 after purchasing an additional 47,213 shares during the period. Institutional investors and hedge funds own 54.21% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis.

Featured Article: What is the accumulation/distribution indicator?

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.